Graphene Investments SAS Reduces Stock Position in Eli Lilly and Company (NYSE:LLY)

Graphene Investments SAS decreased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 24.4% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 3,100 shares of the company's stock after selling 1,000 shares during the period. Graphene Investments SAS's holdings in Eli Lilly and Company were worth $2,560,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Holistic Planning LLC bought a new position in Eli Lilly and Company during the 1st quarter valued at approximately $237,000. PDS Planning Inc raised its holdings in shares of Eli Lilly and Company by 13.4% during the first quarter. PDS Planning Inc now owns 6,722 shares of the company's stock valued at $5,552,000 after acquiring an additional 796 shares in the last quarter. Kaufman Rossin Wealth LLC purchased a new stake in Eli Lilly and Company in the first quarter worth $242,000. Austin Asset Management Co Inc bought a new stake in Eli Lilly and Company in the first quarter valued at $3,084,000. Finally, GenTrust LLC increased its position in Eli Lilly and Company by 1.9% during the 1st quarter. GenTrust LLC now owns 877 shares of the company's stock valued at $724,000 after purchasing an additional 16 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 0.4%

Shares of NYSE:LLY traded down $3.18 during trading on Tuesday, reaching $776.36. 2,029,024 shares of the stock traded hands, compared to its average volume of 3,674,882. The stock has a market cap of $735.78 billion, a P/E ratio of 63.25, a price-to-earnings-growth ratio of 1.13 and a beta of 0.41. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The stock has a 50-day moving average of $779.41 and a two-hundred day moving average of $800.01. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business's revenue was up 45.2% compared to the same quarter last year. During the same period last year, the company posted $2.58 earnings per share. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.77%. Eli Lilly and Company's payout ratio is 48.82%.

Analysts Set New Price Targets

LLY has been the subject of several research analyst reports. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price on the stock. Wall Street Zen cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $1,011.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.